A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

  title={A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction},
  author={Michael Philipp and Ralph Kohnen and Otto Benkert},
  journal={International Clinical Psychopharmacology},
A double-blind parallel-group comparison study of moclobemide versus doxepin in 237 patients with major depression confirmed that moclobemide was equal in efficacy and better tolerated than doxepin. It was less sedating and caused fewer anticholinergic adverse events as measured by the UKU side-effect rating scale. Unexpectedly, moclobemide therapy more often than doxepin resulted in increased sexual desire. An exploratory analysis of UKU-measured symptoms of impaired sexual function prior to… Expand
Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults
In patients for whom sexual function is important or sexual dysfunction is present, moclobemide should be considered a first line antidepressant. Expand
A double‐blind comparison of moclobemide and doxepin in depressed general practice patients
Improvement was negatively correlated with age; this was statistically significant in the total group as well as in the MOC group, with a nonsignificant trend in the same direction in the DOX group. Expand
The effects of moclobemide on sexual desire and function in healthy volunteers
In both men and women there were no differences between moclobemide and placebo on measures of sexual desire and function, however, men andWomen differed in the levels of reported interest and sexual performance. Expand
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Open-ended questions are an insufficient tool to estimate sexual dysfunction, and premarketing clinical trials should therefore include basic explicit assessments, and the failure to find a correlation between treatment duration and sexual dysfunction adds to the notion that sexual side effects due to SSRIs do not abate over time. Expand
Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction
The hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties is supported. Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
The incidence of sexual dysfunction with SSRIs and venlafaxine is high, ranging from 58% to 73%, as compared with serotonin-2 (5-HT2) blockers (nefazodone and mirtazapine), moclobemide, and amineptine. Expand
Assessment of sexual dysfunction in depressed patients and reporting attitudes in routine daily practice: Results of the postmarketing observational studies with moclobemide, a reversible MAO-A inhibitor.
The results of the observational studies with moclobemide do not provide evidence that moclOBemide induces or intensifies sexual dysfunction in depressed patients under routine daily treatment and demonstrate that the assessment of sexual function in the practice is clearly influenced by the reporting attitudes of patients and physicians. Expand
Sexual dysfunction and antidepressants.
  • J. Davidson
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 1996
It is suggested that men and women, depressives and non-depressives, are both at risk for sexual side effects and availability of a simple, easy to use, analogue-type scale would facilitate research, and perhaps enhance the use of antidepressant drugs. Expand
Moclobemide versus fluoxetine for a major depressive episode
Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclopemide/day can still improve the patient's condition, while 40 mg fluoxettine/day does not. Expand